What You Should Know:
– Healthcare technology company Aetion announced today a $110M Series C fundraise, led by Warburg Pincus, a leading global growth equity firm, with additional investments from B Capital and Foresite Capital. Aetion’s existing backers New Enterprise Associates (NEA) and Flare Capital Partners also joined the round. Aetion has raised a total of $212M to date.
– The company will use the new funds to extend the capabilities of its Aetion Evidence Platform, expand its European and Asian-Pacific footprint, and grow its commercial team in order to serve the growing demand from biopharma, payer and medical device / diagnostics customers.
– The capital infusion supports Aetion’s continued growth and industry leadership in the real-world evidence (RWE) space. In the last year alone, Aetion nearly doubled revenue and secured 100 percent of customer renewals while establishing valuable industry collaborations.
– Aetion became the first RWE company to establish an FDA COVID-19 Research Collaboration Agreement and was selected by ICER as its preferred RWE partner and platform.
Better Decisions Guided by Real-World Evidence
Aetion Evidence Platform focuses on patient outcomes because that’s what matters in a value-based system. By using real-world data generated by the health care system and analyses grounded in epidemiology, we enable you to make validated decisions at every phase of commercialization and across the risk-bearing continuum. Because a new era of health care relies on transparent, shared, and validated evidence.
“In a post-COVID era, we have an imperative to use rapid, rigorous evidence to inform health care decisions,” said Aetion CEO, Carolyn Magill. “This investment reinforces Aetion’s position as an RWE leader and our potential for future growth, as we enable our customers to generate regulatory-grade evidence at scale.”
